ImmunoPharma AS   Report issue

For profit Phase 3
Founded: Oslo Norway (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2011
NCT01496053
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ImmunoPharma AS

Active Ingredients

Drugs in Phase 3 Trials (1)

agaricus blazei murill (2 trials)

Drugs in Other Trials (1)

andosan (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 3)

Inflammatory Bowel Diseases (Phase 3)

Intestinal Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2